Biocartis–TopBio1: investment, 201711 DIVESTMENT off all shares (above 3% before) by TopBio1 LP

	Period	2017-11-14
	Money taker	Biocartis Group N.V. (Euronext Brussels: BCART)
	Group	Biocartis (Group)
	Money source	TopBio1 LP (Cayman Islands)
	Product	venture capital
	Product 2	Idylla™ molecular diagnostics system

Biocartis Group N.V.. (11/14/17). "Press Release: Disclosure of a Transparency Notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings)". Mechelen.

Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the ‘Belgian Transparency Act’), that it received a transparency notification dated 10 November 2017 (the ‘Notification’), indicating that as a result of the disposal of voting securities on 7 November 2017, TopBio1 LP crossed the lowest notification threshold of 3%. As a result, TopBio1 LP no longer holds voting securities or voting rights in Biocartis.

The Notification contains the following information:

> Reason for the Notification: Downward crossing of the lowest threshold. Acquisition or disposal of voting securities or voting rights.

> Notification by: A person that notifies alone.

> Persons subject to the notification requirement: TopBio1 LP, 89 Nexus Way, 2nd Floor, Camana Bay, P.O. Box 31106, Grand Cayman, KY1-1205 Cayman Islands.

> Transaction date: 7 November 2017.

> Threshold that is crossed: 3%.

> Denominator: 44,669,772.

> Details of the Notification: TopBio1 LP no longer holds voting securities or voting rights in Biocartis.

> Chain of controlled undertakings through which the holding was effectively being held: TopBio1 LP is not a controlled entity.

The Notification is available here on the website of the Company.

Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (‘FSMA’) is required by all natural and legal persons in each case where the percentage of voting rights in the Company held by such persons reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

----- END -----

More information:

Renate Degrave
Manager Corporate Communications & Investor Relations Biocartis
email rdegrave@biocartis.com
tel +32 15 631 729 | mobile +32 471 53 60 64
@Biocartis_ | www.linkedin.com/Biocartis

About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis’ proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla™ platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers ten oncology tests and two infectious disease tests in Europe. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.

The Biocartis trademark and logo are trademarks of Biocartis and are used and registered in Europe. Idylla™ is a registered trademark in the United States and other countries. The Idylla™ trademark and logo are trademarks of and used by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.

Forward-looking statements

This press release may contain forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements speak only as of the date of this press release. Biocartis expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release. You should not place undue reliance on forward-looking statements.